Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
- Registration Number
- NCT02236715
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1039
Inclusion Criteria
- Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion Criteria
- Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Obstructive Airways Disease Atrovent® -
- Primary Outcome Measures
Name Time Method Change in total severity of the clinical picture rated on a 4-point scale after 4 weeks
- Secondary Outcome Measures
Name Time Method Assessment of efficacy by patient on a 4-point scale after 4 weeks Assessment of tolerability by patient on a 4-point scale after 4 weeks Number of patients with adverse drug reactions up to 4 weeks Assessment of efficacy by investigator on a 4-point scale after 4 weeks Assessment of tolerability by investigator on a 4-point scale after 4 weeks